ASH 2024: Breakthrough Insights on CAR T-Cell Therapy for Relapsed/Refractory ALL - Episode 9
Panelists discuss collaboration strategies for chimeric antigen receptor (CAR) T-cell therapy referral, reflections on advancements in relapsed/refractory acute lymphoblastic leukemia (R/R ALL) throughout 2024, key accomplishments, and future opportunities for progress in 2025.
This is a modal window.
Video content above is prompted by the following:
Closing